Decorative
Investor Day “CB1 Axis: Unlocking the Pharmaceutical Potential of the Endocannabinoid System”

Investor Day “CB1 Axis: Unlocking the Pharmaceutical Potential of the Endocannabinoid System”

Investor Day “CB1 Axis: Unlocking the Pharmaceutical Potential of the Endocannabinoid System”

Skye Bioscience hosted a virtual Investor Day on October 25, 2023 featuring Brian Levy, O.D. (former CMO, Aerie and Bausch & Lomb), Glenwood Gum, Ph.D. (Pharmaron), and Sameh Mosaed, M.D., Ph.D. (UC Irvine), who provided an overview of the current glaucoma commercial landscape, drug development pipeline, and perspective on the historical challenges to achieving CB1-targeting therapeutics for the treatment of glaucoma.

Skye leadership provided broad insight into SBI-100 Ophthalmic Emulsion, its CB1 agonist being developed to potentially treat glaucoma, including a nonclinical data overview, clinical data from our recently completed Phase 1 study, a Phase 2 clinical update, and an outline of the glaucoma market opportunity and Skye’s positioning strategy.

Watch the replay here: Watch the Investor Day Presentation

View the Investor Day slide deck here: Investor Day Presentation Download

Connect with us:

Twitter: @SkyeBioscience
LinkedIn: https://www.linkedin.com/company/skyebioscience
Facebook: https://www.facebook.com/skyebioscience
Newsletter: https://mailchi.mp/21355b06b667